Kiniksa Pharmaceuticals International
KNSA
77.96
+0.87
+1.13%
Kiniksa Pharmaceuticals International
US · KNSA
#1938 by market cap
Listed 2018
77.96
+0.87
+1.13%
Live - 5344 symbols - heartbeat 141s ago
· 2026-10-07 19:54
After-hours
78.50
+0.69%
- Market cap
- 6.08B
- P/E (TTM)i
- 78.75
- P/Bi
- 9.30
- EPSi
- 0.75
- Div yieldi
- 0.00%
- 52W posi
- 90%
Reader sentiment
Are you bullish or bearish on KNSA?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 19.60, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +60.09% YoY
Margins
- Gross margin
- 54.66%
- Operating margin
- 11.40%
- Net margin
- 8.71%
Key ratios & quality
- Altman Z-Scorei
- 19.60
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | 0 | 0 | 38.54M | 220.18M | 270.26M | 423.24M | 677.56M |
| Gross profit | -- | 0 | 0 | 28.61M | 173.21M | 180.33M | 234.02M | 370.35M |
| Selling & admin expenses | 21.56M | 34.96M | 45.32M | 85.95M | 97.95M | 129.43M | 168.01M | 196.27M |
| Research & development | 86.60M | 135.00M | 112.04M | 99.30M | 65.49M | 76.10M | 111.62M | 96.85M |
| Operating profit | -108.16M | -169.96M | -157.36M | -156.64M | 9.77M | -25.20M | -45.62M | 77.22M |
| Pretax profit | -103.44M | -163.91M | -156.23M | -156.54M | 11.03M | -16.65M | -36.15M | 88.87M |
| Tax | -214.00K | -2.05M | 5.15M | 1.39M | -172.34M | -30.74M | 7.04M | 29.86M |
| Net profit | -103.23M | -161.87M | -161.38M | -157.92M | 183.36M | 14.08M | -43.19M | 59.01M |
| Basic EPS | -3 | -3 | -3 | -2 | 3 | 0 | -1 | 1 |
| Diluted EPS | -3.49 | -2.99 | -2.61 | -2.30 | 2.60 | 0.20 | -0.60 | 0.75 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 137.79M | 156.80M | 180.86M | 202.13M | 214.27M | 243.60M |
| Gross profit | 76.13M | 85.78M | 97.29M | 111.15M | 117.89M | 131.96M |
| Selling & admin expenses | 43.53M | 46.86M | 49.10M | 56.78M | 61.15M | 63.87M |
| Research & development | 19.33M | 18.75M | 24.17M | 34.61M | 27.48M | 40.90M |
| Operating profit | 13.27M | 20.16M | 24.02M | 19.77M | 29.27M | 27.19M |
| Pretax profit | 15.57M | 22.88M | 27.16M | 23.27M | 32.68M | 31.15M |
| Tax | 7.03M | 5.05M | 8.72M | 9.07M | 10.09M | 5.71M |
| Net profit | 8.54M | 17.83M | 18.44M | 14.20M | 22.59M | 25.43M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.11 | 0.23 | 0.23 | 0.17 | 0.27 | 0.30 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 313.75M | 241.63M | 333.25M | 196.45M | 243.06M | 276.30M | 331.80M | 527.18M |
| Cash & ST investments | 307.30M | 233.38M | 323.48M | 182.20M | 190.61M | 206.37M | 243.63M | 414.07M |
| Inventory | -- | -- | 0 | 3.68M | 21.60M | 31.12M | 26.36M | 54.90M |
| Total assets | 321.97M | 254.53M | 349.46M | 232.80M | 459.67M | 526.32M | 580.55M | 763.63M |
| Total current liabilities | 42.55M | 27.83M | 31.85M | 44.82M | 47.07M | 63.67M | 100.62M | 139.18M |
| Short-term debt | -- | 1.70M | 2.11M | 3.38M | 3.30M | 2.25M | 1.99M | 2.99M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 42,698,000.00 | 29,111,000.00 | 37,529,000.00 | 47,763,000.00 | 63,523,000.00 | 87,483,000.00 | 142,117,000.00 | 196,027,000.00 |
| Total equity | 279.27M | 225.42M | 311.94M | 185.04M | 396.15M | 438.84M | 438.44M | 567.61M |
| Retained earnings | -194.23M | -356.09M | -517.47M | -675.40M | -492.03M | -477.95M | -521.14M | -462.14M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 355.91M | 420.31M | 475.53M | 527.18M | 594.17M | 668.63M |
| Cash & ST investments | 268.34M | 307.78M | 352.10M | 414.07M | 468.09M | 525.93M |
| Inventory | 22.07M | 48.18M | 41.40M | 54.90M | 73.14M | 70.93M |
| Total assets | 599.33M | 661.15M | 712.33M | 763.63M | 825.28M | 896.11M |
| Total current liabilities | 97.27M | 117.83M | 123.59M | 139.18M | 156.61M | 171.25M |
| Short-term debt | 2.29M | 2.52M | 2.70M | 2.99M | 3.17M | 4.01M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 141,837,000.00 | 166,143,000.00 | 176,950,000.00 | 196,027,000.00 | 219,593,000.00 | 241,961,000.00 |
| Total equity | 457.49M | 495.01M | 535.38M | 567.61M | 605.69M | 654.15M |
| Retained earnings | -512.60M | -494.77M | -476.34M | -462.14M | -439.55M | -414.11M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -81.01M | -158.37M | -136.53M | -126.30M | 5.81M | 13.30M | 25.69M | 137.99M |
| Depreciation & amortization | 286.00K | 2.07M | 2.41M | 2.36M | 2.40M | 2.34M | 1.70M | 1.55M |
| Free cash flow | -86.30M | -161.57M | -136.82M | -146.71M | 5.70M | 13.17M | 25.41M | 136.42M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 159.19M | 83.11M | 228.22M | 0 | -901.00K | -2.21M | -4.98M | -7.73M |
| Ending cash balance | 72.19M | 47.14M | 114.25M | 122.47M | 122.72M | 107.95M | 183.58M | 165.60M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 22.32M | 28.09M | 33.68M | 53.89M | 50.20M | 47.20M |
| Depreciation & amortization | 345.00K | 358.00K | 384.00K | 467.00K | 468.00K | 472.00K |
| Free cash flow | 22.23M | 27.93M | 33.01M | 53.26M | 50.04M | 46.53M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -412.00K | -2.05M | -4.35M | -918.00K | -316.00K | -5.47M |
| Ending cash balance | 157.13M | 192.04M | 174.86M | 165.60M | 189.95M | 175.68M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -108.91 | -64.15 | -60.06 | -63.55 | 63.10 | 3.37 | -9.85 | 11.73 |
| ROA %i | -55.88 | -56.16 | -53.44 | -54.24 | 52.96 | 2.86 | -7.80 | 8.78 |
| ROIC %i | -113.88 | -65.82 | -59.31 | -61.96 | 61.49 | 3.30 | -9.61 | 11.51 |
| 5-year avg ROE %i | -- | -- | -- | -- | -46.72 | -24.26 | -13.40 | 0.96 |
| EBIT margin %i | -- | -- | -- | -406.38 | 4.44 | -9.32 | -10.78 | 11.40 |
| FCF / sales %i | -- | -- | -- | -- | 2.59 | 4.87 | 6.00 | 20.13 |
| Current ratioi | 7.37 | 8.68 | 10.46 | 4.38 | 5.16 | 4.34 | 3.30 | 3.79 |
| Quick ratioi | 7.22 | 8.39 | 10.16 | 4.15 | 4.48 | 3.58 | 2.84 | 3.09 |
| Debt / assetsi | 0.00 | 1.04 | 2.00 | 2.60 | 1.29 | 2.33 | 1.70 | 1.24 |
| LT debt / equityi | -- | 0.42 | 1.56 | 1.44 | 0.66 | 2.28 | 1.79 | 1.15 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | 0.00 | 0.00 | -- | -- | -- | 122.27 | 45.45 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -31.47 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | 188.15 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -3.81 | 1.03 | 7.39 | 11.73 | 13.74 | 14.04 |
| ROA %i | -3.03 | 0.80 | 5.67 | 8.78 | 10.26 | 10.36 |
| ROIC %i | -3.72 | 1.01 | 7.24 | 11.51 | 13.50 | 13.81 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -3.28 | 0.85 | 6.38 | 11.40 | 12.36 | 11.92 |
| FCF / sales %i | 9.09 | 12.56 | 17.01 | 20.13 | 21.78 | 21.74 |
| Current ratioi | 3.66 | 3.57 | 3.85 | 3.79 | 3.79 | 3.90 |
| Quick ratioi | 3.17 | 2.88 | 3.27 | 3.09 | 3.14 | 3.21 |
| Debt / assetsi | 1.65 | 1.48 | 1.36 | 1.24 | 1.09 | 0.99 |
| LT debt / equityi | 1.67 | 1.46 | 1.31 | 1.15 | 0.97 | 0.75 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product revenue, net100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.